Yesterday, Emperor Fauci was on Bloomberg. David Westin says: "Dr. Fauci, I had two covid shots, a booster, and then after that I got covid. When do you think I will be ready for another booster shot?" SIGH!!!!!!!!!!!!!!!
When are people going to realize that Fauci, Biden, Pelosi, Cuomo, Newsom, and the rest of the Covid Nazis dont give a shit about them. Masks and vaccines are about obedience. Make no mistake. https://news.yahoo.com/second-covid-booster-shot-extends-012300452.html Second COVID booster shot extends protection for just a few weeks, study shows
Appeals court OKs Biden federal employee vaccine mandate In a 2-1 ruling, a panel reversed a lower court and ordered dismissal of a lawsuit challenging the mandate. NEW ORLEANS — President Joe Biden’s requirement that all federal employees be vaccinated against COVID-19 was upheld Thursday by a federal appeals court. In a 2-1 ruling, a panel of the 5th Circuit Court of Appeals reversed a lower court and ordered dismissal of a lawsuit challenging the mandate. The ruling, a rare win for the administration at the New Orleans-based appellate court, said the federal judge didn’t have jurisdiction in the case and that those challenging the requirement could have pursued administrative remedies under Civil Service law. U.S. District Judge Jeffrey Brown, who was appointed to the District Court for the Southern District of Texas by President Donald Trump, had issued a nationwide injunction against the requirement in January. When the case was argued at the 5th Circuit last month, administration lawyers had noted that district judges in a dozen jurisdictions had rejected a challenge to the vaccine requirement for federal workers before Brown ruled. The administration argued that the Constitution gives the president, as the head of the federal workforce, the same authority as the CEO of a private corporation to require that employees be vaccinated. Lawyers for those challenging the mandate had pointed to a recent Supreme Court opinion that the government cannot force private employers to require employee vaccinations. Twelve of 17 active judges at the 5th Circuit were nominated to the court by Republicans, including six Trump appointees. Judges Carl Stewart and James Dennis, both nominated to the court by President Bill Clinton, were in the majority. Judge Rhesa Barksdale, a senior judge nominated by President George H.W. Bush, dissented, saying the relief the challengers sought does not fall under the Civil Service Reform act cited by the administration. The case marked ideological divides at the appeals court even before Thursday’s ruling. A different panel had refused in February to block Brown’s ruling pending the appeal. That panel’s vote was 2-1. There were no reasons given by the majority — Judge Jerry Smith, a President Ronald Reagan nominee, and Don Willett, a Trump nominee. But there was a lengthy dissent by Judge Stephen Higginson, a nominee of President Barack Obama, who said a single district judge “lacking public health expertise and made unaccountable through life tenure,” should not be able to block the president from ordering the same type of COVID-19 safety measures many private sector CEOs have ordered. https://www.politico.com/news/2022/04/07/biden-vaccine-mandate-appeals-court-00023972 wrbtrader
Hey everybody, go look over there, a Shiny Object Biden thinggg. Yawwwnn(*) https://www.elitetrader.com/et/threads/latest-vaccine-news.343809/page-235#post-5575539
Omicron-specific Sinopharm, Sinovac COVID vaccine candidates cleared for clinical trial https://www.reuters.com/business/he...candidates-cleared-clinical-trial-2022-04-16/ COVID-19 vaccine candidates developed by a Sinopharm subsidiary and Sinovac Biotech (SVA.O) to target the Omicron variant were approved for clinical trials in Hong Kong, the companies said on Saturday. Scientists worldwide are racing to study upgraded injections against Omicron, as data indicated that antibodies elicited by vaccines based on older strains show weaker activity to neutralise the highly transmissible variant. The two candidates from units of Sinopharm subsidiary China National Biotec Group (CNBG) and one from Sinovac contain inactivated or "killed" coronavirus and are similar to vaccines that the companies are supplying in China and overseas, the companies said in statements. The Sinopharm candidates will be tested as boosters in adults who have already received two or three vaccine doses, CNBG said. It did not specify which vaccine products the trial participants would have received before taking the experimental booster, or how many subjects would be recruited. Sinovac said it will push forward studies in its existing CoronaVac vaccine's protection against emerging variants. A Chinese study showed that a fourth dose of BBIBP-CorV, an existing Sinopharm COVID vaccine, did not significantly lift antibody levels against Omicron when administered six months after a third booster dose to a regular two-dose regimen. While the fourth dose restored antibody levels to around the peaks that followed the third dose, researchers said new vaccines would offer a better alternative as future boosters.
COVID-19 booster shot used for children 5-11 strengthens immune response: Pfizer https://www.theglobeandmail.com/wor...ot-used-for-children-5-11-strengthens-immune/ A booster shot of the coronavirus vaccine made by Pfizer-BioNTech increased the level of neutralizing antibodies against both the original version of the virus and the omicron variant in a small trial of children age 5 to 11, the companies announced Thursday. If the companies’ claims of a strong immune response pass muster with federal regulators, the government could broaden eligibility for booster doses to include 28 million more children. The study by Pfizer and BioNTech, announced in December, included 140 children who received a booster six months after their second shot. The findings were described in a news release. The children showed a sixfold increase in antibody levels against the original version of the virus one month after receiving the booster, compared with one month after receiving a second dose. Laboratory tests of blood samples from a subgroup of 30 children also showed 36 times the level of neutralizing antibodies against the omicron variant compared with levels after only two doses, according to the news release and a Pfizer spokeswoman. The study did not show how long the antibodies last, or test effectiveness against COVID. The data was not published or peer-reviewed, and at least one expert said it was impossible to assess the study without more information. Antibodies are the immune system’s first line of defense against infection. They are expected to rise after an additional dose; how rapidly that protection wanes has been an enduring concern for vaccine experts, regulators and manufacturers. The companies said they would ask the Food and Drug Administration for emergency authorization of a booster for 5- to 11-year-olds “in the coming days.” The agency has typically acted within a month of receiving such requests. Currently, Americans 12 and older are eligible for at least one booster, and about 30 million people age 50 or older are eligible for a second one. Studies suggest that 5- to 11-year-olds may particularly need a booster. Researchers in New York state recently found that while two Pfizer shots protected children in that age group from serious illness, they provided virtually no protection against symptomatic infection, even just a month after full immunization. “I think a bottom line is that in order to protect from the omicron, we know from studies and from adults and adolescents that you need three doses,” said Dr. Kathryn M. Edwards, a pediatric vaccine expert at Vanderbilt University School of Medicine. She predicted regulators would authorize the companies’ request. But Dr. Philip Krause, who recently retired as a senior vaccine regulator at the FDA, questioned whether the sixfold increase in antibody levels in the overall group was the result of the additional shot or infection with the virus in the six month interim between the second and third dose. “There are a lot of very important details that are missing,” he said of the companies’ statement. Dr. Ofer Levy, a vaccine expert at Boston Children’s Hospital and a member of the FDA’s vaccine advisory board, said the results were helpful but the trial was modest in size, and no outcomes of safety or efficacy were cited. “We presume that a higher level of antibodies is better and that’s probably true,” he said. “But how does that translate into vaccine effectiveness? We haven’t fully sorted that out.”